Developing Improved Prognostics for Mantle-Cell Lymphoma
August 21, 2013

While treatments exist for mantle-cell lymphoma (MCL), a cancer of the cells of the immune system, the condition is currently incurable.  MCL leads to uncontrolled growth of defective immune cells, leading to the swelling of lymph glands that ultimately compromises the ability of the immune system to function.  The aggressiveness of MCL varies widely and treatments range from observation-alone approaches for less aggressive MCL to highly invasive chemotherapies and, in the worst cases, bone marrow transplants to replace the immune systems of patients.
Currently, physicians lack the ability to confidently identify MCL severity or to predict treatment impact on progression of this disease.

In order to meet the need for higher performance prognostic tools, OCI Senior Scientist Dr. Suzanne Kamel-Reid and her colleagues Dr. Michael Crump (Medical Oncologist, Princess Margaret Cancer Centre) and Dr. Rashmi Goswami (Postdoctoral Fellow, OCI) analyzed a large set of tumour samples from MCL patients.  Their studies led to the identification of 14 microRNAs - molecules known to be involved in cancer severity - that were implicated in MCL aggressiveness.  By combining one of the microRNAs identified (known as miR-127-3p) with existing prognostics, Dr. Kamel-Reid and co-workers were able to devise new and superior prognostic models for MCL.  While clinical trials are required to test the usefulness of these models in patients, the identified microRNAs may help physicians better customize treatments for patients, and will serve as the basis for new studies into the molecular mechanisms underlying MCL severity.

This work was supported by the Irving and Mary Storfer Mantle-Cell Lymphoma Research Fund, The Princess Margaret Cancer Foundation, the Cancer Research Society, the Galloway Fund and the Ontario Ministry of Health and Long-Term Care.

Source: NRx, July 2013
You have an old version of Adobe's Flash Player. Get the latest Flash player.